An Open Label Pilot Trial of Guselkumab (Tremfya) in the Treatment of Adults With Pityriasis Rubra Pilaris (PRP)®
Open label is a term used to describe the situation when both the researcher and the participant in a research study know the treatment the participant is receiving. Open-label is the opposite of double-blind when neither the researcher nor the participant knows what treatment the participant is receiving.
Sponsor
Oregon Health and Science University
Summary
✽ 15 patients with PRP will be treated with guselkumab for 20 weeks to determine safety and efficacy.
✽ Participants are required to travel to Portland, Oregon for the first visit, week-4 visit, and week-24 visit.
✽ Three visits in between these times and one follow up visit may be performed by secure videoconferencing.
Estimated Enrollment: 15 participants
Estimated Study Completion Date: December 2020
Basic Eligibility
✽ Diagnosis of PRP by clinical assessment
✽ Male or female age 18-99
STEP ONE:
Read the information detailing the OHSU PRP research effort at ClinicalTrials.gov, National Institutes of Health, U.S. National Library of Medicine.
Go to https://clinicaltrials.gov/ct2/show/NCT03975153?cond=pityriasis+rubra+pilaris&draw=2&rank=2
STEP TWO: Contact Dr. Teri Greiling, MD directly.